Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNexus Gene Lab (BGLC) Return on Equity (2019 - 2025)

Historic Return on Equity for BioNexus Gene Lab (BGLC) over the last 7 years, with Q3 2025 value amounting to 0.32%.

  • BioNexus Gene Lab's Return on Equity fell 2300.0% to 0.32% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.32%, marking a year-over-year decrease of 2300.0%. This contributed to the annual value of 0.18% for FY2024, which is 1400.0% up from last year.
  • As of Q3 2025, BioNexus Gene Lab's Return on Equity stood at 0.32%, which was down 2300.0% from 0.38% recorded in Q2 2025.
  • In the past 5 years, BioNexus Gene Lab's Return on Equity ranged from a high of 0.19% in Q4 2021 and a low of 0.38% during Q2 2025
  • In the last 5 years, BioNexus Gene Lab's Return on Equity had a median value of 0.08% in 2023 and averaged 0.1%.
  • As far as peak fluctuations go, BioNexus Gene Lab's Return on Equity plummeted by -4500bps in 2023, and later soared by 2900bps in 2024.
  • Over the past 5 years, BioNexus Gene Lab's Return on Equity (Quarter) stood at 0.19% in 2021, then crashed by -120bps to 0.04% in 2022, then crashed by -596bps to 0.27% in 2023, then surged by 34bps to 0.18% in 2024, then tumbled by -82bps to 0.32% in 2025.
  • Its Return on Equity was 0.32% in Q3 2025, compared to 0.38% in Q2 2025 and 0.26% in Q1 2025.